This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Landstedt-Hallin, L. Articles by Lins, P.-E. Search for Related Content PubMed PubMed Citation Articles by Landstedt-Hallin, L. Articles by Lins, P.-E.

Oral Glibenclamide Suppresses Glucagon Secretion during Insulin-Induced Hypoglycemia in Patients with Type 2 Diabetes¹

Division of Internal Medicine, Karolinska Institute, Danderyd Hospital, S-182 88 Danderyd, Sweden

Address all correspondence and requests for reprints to: Dr. Lena Landstedt-Hallin, Division of Internal Medicine, Karolinska Institute, Danderyd Hospital, S-182 88 Danderyd, Sweden.

Intensifying pharmacological therapy in patients with type 2 diabetes increases the risk of hypoglycemia and often requires the simultaneous use of more than one agent. Combining insulin and sulfonylurea is an effective and frequently used therapy in such patients. However, sulfonylurea derivatives have been shown to affect the release of glucagon, indicating a possible effect of such therapy on hormonal counterregulation to hypoglycemia. Thirteen patients receiving combined therapy were studied on two occasions: 1) after a wash-out period of glibenclamide (-GLIB), and 2) after resuming combined treatment for 6 months (+GLIB). We performed nonstepwise, hyperinsulinemic hypoglycemic clamps using a constant iv insulin infusion and clamping blood glucose at 2.7 mmol/L (48 mg/dL) for 60 min. C Peptide levels were significantly higher during +GLIB, but no significant differences were seen in peripheral plasma insulin levels (+GLIB mean ± SD, 70 ± 17 mU/L vs. -GLIB, 75 ± 14; P = 0.26). Epinephrine responses were similar in the two tests, but when glibenclamide was present the glucagon response was smaller, both the peak value (P = 0.016) and the incremental area under the curve (P = 0.011) as well as the total area under the curve (P = 0.016). These results suggest that intraislet insulin secretion is of importance for the -cell responsiveness to hypoglycemia in these patients.

This article has been cited by other articles:

				I. Quesada, E. Tuduri, C. Ripoll, and A. Nadal Physiology of the pancreatic {alpha}-cell and glucagon secretion: role in glucose homeostasis and diabetes J. Endocrinol., October 1, 2008; 199(1): 5 - 19. [Abstract] [Full Text] [PDF]

				J. Gromada, I. Franklin, and C. B. Wollheim {alpha}-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains Endocr. Rev., February 1, 2007; 28(1): 84 - 116. [Abstract] [Full Text] [PDF]

				N. N. Zammitt and B. M. Frier Hypoglycemia in Type 2 Diabetes: Pathophysiology, frequency, and effects of different treatment modalities Diabetes Care, December 1, 2005; 28(12): 2948 - 2961. [Full Text] [PDF]

				J. Gromada, X. Ma, M. Hoy, K. Bokvist, A. Salehi, P.-O. Berggren, and P. Rorsman ATP-Sensitive K+ Channel-Dependent Regulation of Glucagon Release and Electrical Activity by Glucose in Wild-Type and SUR1-/- Mouse {alpha}-Cells Diabetes, December 1, 2004; 53(suppl_3): S181 - S189. [Abstract] [Full Text] [PDF]

				H. Zhou, P. O. T. Tran, S. Yang, T. Zhang, E. LeRoy, E. Oseid, and R. P. Robertson Regulation of {alpha}-Cell Function by the {beta}-Cell During Hypoglycemia in Wistar Rats: the "Switch-off" Hypothesis Diabetes, June 1, 2004; 53(6): 1482 - 1487. [Abstract] [Full Text] [PDF]

				K. M. Hope, P. O. T. Tran, H. Zhou, E. Oseid, E. Leroy, and R. P. Robertson Regulation of {alpha}-Cell Function by the {beta}-Cell in Isolated Human and Rat Islets Deprived of Glucose: the "Switch-off" Hypothesis Diabetes, June 1, 2004; 53(6): 1488 - 1495. [Abstract] [Full Text] [PDF]

				T. Ostergard, K. B. Degn, M.-A. Gall, R. D. Carr, J. D. Veldhuis, M. K. Thomsen, R. A. Rizza, and O. Schmitz The Insulin Secretagogues Glibenclamide and Repaglinide Do Not Influence Growth Hormone Secretion in Humans but Stimulate Glucagon Secretion during Profound Insulin Deficiency J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 297 - 302. [Abstract] [Full Text] [PDF]

				K. Cejvan, D. H. Coy, J. J. Holst, E. Cerasi, and S. Efendic Gliclazide Directly Inhibits Arginine-Induced Glucagon Release Diabetes, December 1, 2002; 51(90003): S381 - 384. [Abstract] [Full Text] [PDF]

				R. J. McCrimmon, M. L. Evans, R. J. Jacob, X. Fan, Y. Zhu, G. I. Shulman, and R. S. Sherwin AICAR and phlorizin reverse the hypoglycemia-specific defect in glucagon secretion in the diabetic BB rat Am J Physiol Endocrinol Metab, November 1, 2002; 283(5): E1076 - E1083. [Abstract] [Full Text] [PDF]

				S. Banarer, V. P. McGregor, and P. E. Cryer Intraislet Hyperinsulinemia Prevents the Glucagon Response to Hypoglycemia Despite an Intact Autonomic Response Diabetes, April 1, 2002; 51(4): 958 - 965. [Abstract] [Full Text] [PDF]

				E. W.M.T. ter Braak, A. M.M.F. Appelman, I. van der Tweel, D. W. Erkelens, and T. W. van Haeften The Sulfonylurea Glyburide Induces Impairment of Glucagon and Growth Hormone Responses During Mild Insulin-Induced Hypoglycemia Diabetes Care, January 1, 2002; 25(1): 107 - 112. [Abstract] [Full Text] [PDF]